MiNK Therapeutics Stock Sees Bearish Sentiment on KDJ Death Cross, Marubozu Pattern

According to the 15-minute chart of MiNK Therapeutics, there has been a significant shift in the momentum of the stock price, as indicated by the KDJ Death Cross and Bearish Marubozu at 08/25/2025 14:30. This suggests that the selling pressure is currently dominant in the market, leading to a downward trend in the stock's price, and it is likely to continue in this direction.

Lexington, Mass.-- (BUSINESS WIRE)--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leading immuno-oncology company, will host a virtual Stakeholder Briefing on August 27, 2025, at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of cancer treatment. The agenda includes a strategic and financial overview, achievements tied to the Zydus partnership closing, patient needs fueling interest in colorectal cancer (CRC) studies, recent data from the botensilimab (BOT) and balstilimab (BAL) program, and an overview of the Phase 3 BATTMAN study in metastatic CRC—plus highlights of upcoming milestones and potential breakthroughs in immuno-oncology. The session will conclude with a live Q&A.

Key Speakers:

- Garo H. Armen, PhD, Founder, Chairman, CEO of Agenus
- Jennifer Buell, PhD, CEO of MiNK Therapeutics/ Chair of Executive Committee of Agenus
- Richard M. Goldberg, MD, Chief Development Officer of Agenus
- Nicholas C. DeVito, MD, Assistant Professor of Medical Oncology at Duke University
- Chris O'Callaghan, DVM, MSc, PhD, & Jonathan Loree, MD, MS, FRCPC (CCTG): Senior Investigators at Canadian Cancer Trials Group (CCTG)

Agenda Highlights:

- Strategic and financial overview
- Achievements tied to the Zydus partnership closing
- Patient needs fueling interest in CRC studies
- Recent data from the botensilimab (BOT) and balstilimab (BAL) program
- Overview of the Phase 3 BATTMAN study in metastatic CRC
- Highlights of upcoming milestones and potential breakthroughs in immuno-oncology

About Agenus:

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics), and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit [www.agenusbio.com](http://www.agenusbio.com) or @agenus_bio.

About Botensilimab (BOT) and Balstilimab (BAL):

Botensilimab is a multifunctional, human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2.

Forward-Looking Statements:

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the botensilimab and balstilimab clinical programs, expected trial initiations and regulatory plans, and the potential benefits of the combination therapy. Words such as “may,” “believes,” “expects,” “anticipates,” “hopes,” “intends,” “plans,” “forecasts,” “estimates,” “will,” “potential,” “game-changing,” “curative,” and similar expressions are intended to identify forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. Factors that could cause actual results to differ include, but are not limited to, those described under the “Risk Factors” section of Agenus’ most recent Annual Report on Form 10-K for 2024 and subsequent Quarterly Reports on Form 10-Q filed with the SEC. Agenus cautions investors not to place undue reliance on forward-looking statements in this release, which speak only as of the date of this announcement. The company undertakes no obligation to update or revise these statements, except as required by law.

References:

[1] https://www.biospace.com/press-releases/agenus-to-unveil-bot-bal-strategic-advancements-key-milestones-and-future-outlook-in-virtual-stakeholder-briefing-on-august-27-2025